Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.
Metrics to compare | LUMO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLUMOPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.9x | −1.3x | −0.6x | |
PEG Ratio | 0.06 | 0.00 | 0.00 | |
Price/Book | 3.1x | −2.0x | 2.6x | |
Price / LTM Sales | 21.5x | 3.3x | 3.1x | |
Upside (Analyst Target) | 485.2% | 139.6% | 55.7% | |
Fair Value Upside | Unlock | −16.9% | 6.9% | Unlock |